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Background: In sarcoidosis, an antigen specific immune response is a putative mechanism, re-
sulting in granulomatous inflammation. Since the proteasome is involved in antigen presenta-
tion, alterations in the alveolar and parenchymal proteasomal system may be a feature of
sarcoidosis.
Objectives: To explore the role of proteasomes and immunoproteasomes in sarcoidosis.
Methods: Total proteasome concentration and activity was assessed in bronchoalveolar lavage
(BAL) supernatant obtained from sarcoidosis patients (n Z 67) and healthy controls (n Z 18)
using ELISA and cleavage of specific fluorogenic substrates (epoxomicin), respectively. Immu-
nohistochemistry of lung tissue sections and immunocytochemistry of BAL macrophages for im-
munoproteasome was performed in sarcoidosis patients and controls.
Results: Proteasome was present in BAL supernatants of all sarcoidosis patients. In sarcoidosis,
abundant immunoproteasome staining was seen in pneumocytes type II and granulomas. Total
proteasome concentration was greater in active sarcoidosis, stages II (101 ng/ml  79;
p Z 0.009) and III (119 ng/ml  66; p Z 0.012), than in inactive sarcoidosis or in healthyactor a; IL, interleukin; IFNg, interferon g; ARDS, Adult Respiratory Distress Syndrome; SD, standard
DCLO, diffusing capacity of the lung for carbon monoxide; BAL, bronchoalveolar lavage; LDH, lactate
Pathologie, Universita¨tsklinikum Essen, Hufelandstr. 55, D-45122 Essen, Germany. Tel.: þ49 201
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Immunoproteasome in sarcoidosis 1535controls (35 ng/ml  34). In the absence of epoxomicin, all fluorogenic substrates were hydro-
lyzed by BAL supernatant of sarcoidosis patients and controls.
Conclusions: Patients with active sarcoidosis but not healthy controls demonstrate immuno-
proteasome in the lung tissue and in granulomas. Thus, the putative immune response in
sarcoidosis may be mediated or sustained by the proteasomal system.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Sarcoidosis is a systemic disorder of unknown etiology
characterized by noncaseating epithelioid cell granuloma
formation in affected organs including the lung [1].
Sarcoidosis is believed to result from an antigen-specific
immune and inflammatory response to a yet unidentified
antigen [2,3]. Regardless of the specific etiologic basis of
the granulomatous inflammation, the pathologic changes
observed are suggestive of an exaggerated immune
response, and a marked increase in the CD4/CD8 T
lymphocyte ratio is observed in affected organs including
the lung. Effector cells produce pro-inflammatory cyto-
kines, such as Tumor Necrosis Factor a (TNF-a), interleukin-
2 (IL-2), IL-15, IL-18, and interferon-g (IFN-g) resulting in a
Th1 pattern of cytokine production [4e6]. INF-g has also
been noted at sites of disease activity and is produced by
CD4-positive Th1 cells. Production of INF-g along with other
lymphokines induces uncommitted CD4-positive T cells to
differentiate into Th1 effector cells and evokes greater
production of interferon [5]. This inflammatory feed-back
loop may eventually result in the granulomatous response.
It is unknown whether the antigen presumed to evoke
sarcoidosis is processed by the proteasomal system, a sys-
tem involved in many basic cellular processes [7e10] and in
antigen presentation [11]. However, since normal protea-
somal composition is altered by exposure to TNF-a and IFN-
y [12], resulting in the synthesis of immunoproteasomes
[11], and both cytokines are believed to be important me-
diators in sarcoidosis, there might be a link between
sarcoidosis and the immunoproteasome.
The standard 20S proteasome is a multicatalytic enzyme
complex responsible for the degradation of most intracel-
lular proteins and is involved in immune, inflammatory re-
sponses and antigen presentation [7e10]. The 20S
proteasome is a 660e700 kDa multicatalytic proteinase
complex with a cylinder shaped structure composed of
seven a subunits (outer rings) and seven b subunits (inner
rings), respectively [13]. Its proteolytic activities are
characterized by trypsin-, chymotrypsin-, and caspase-like
properties and are exclusively associated with proteasome
subunits b1, b2 and b5.
In cells exposed to IFN-g and TNF-a, catalytic protea-
somal subunits b1i (LMP2), b2i (MECL-1), and b5i (LMP7) are
expressed that replace the constitutive b subunits of the
standard proteasome during proteasome biogenesis thus
forming immunoproteasome [14]. This immunoproteasome
efficiently generates peptides that are loaded on major
histocompatibility complex class-I molecules and presented
to cytotoxic T-lymphocytes [15].Although it was a prior paradigm that the proteasome is
present only intracellularly, it is now accepted that the
proteasome also exists in the extracellular space [16] such
as in plasma or sperm. We reported the extracellular
presence of biologically active 20S proteasome in the
alveolar space of healthy subjects [17] and, in much greater
concentrations, in patients with Adult Respiratory Distress
Syndrome (ARDS) [18,19].
Since sarcoidosis is characterized by an alveolitis with
secretion of proinflammatory mediators [20], we tested the
hypothesis that 1) proteasome is detectable extracellularly
in the alveolar space in pulmonary sarcoidosis but not in
healthy controls; and 2) immunoproteasome is present in
lung tissues affected by sarcoidosis.Methods
Patients and clinical procedures
67 adult patients with sarcoidosis (36 males, 31 females,
mean age: 50years  14.5 standard deviation; SD) were
studied prospectively. The diagnosis was established by one
of the authors (U.C.) on the basis of clinical and radio-
graphic features, histological evidence of noncaseating
granulomas in transbronchial biopsy specimen, and the
exclusion of other granulomatous lung diseases [20]. 27
patients were considered to have active disease and 40 to
have inactive sarcoidosis at the time studied. The criteria
for active disease considering the preceding 3 months
were: 1) recently developed or worsening clinical features
and/or 2) worsening of lung function tests (decrease of the
forced vital capacity/FVC by 10% and/or decrease of
diffusing capacity of carbon monoxide/DLCO by 15%);
and/or 3) progression of chest radiographic findings, i.e.,
increase in densities or new densities (no quantification
done). According to these criteria, 27 patients had wors-
ening clinical features and active disease; 10 of these had
worsening of lung function, and 22 patients had progression
shown by chest X-ray, no patient received corticosteroids.
33% of sarcoidosis patients were ex-smokers, 55% were non-
smokers, and 12% were smokers.
Eighteen adult, non-smoking subjects (8 males, 10 fe-
males, mean age: 48years  15), free of lung, cardiac, in-
fectious, and allergic disease, and without a history of
chemotherapy or radiation therapy served as controls.
Characteristics of sarcoidosis patients and healthy controls
are depicted in Table 1. The study was approved by the
Ethical Committee of the Medical Faculty of the University
of Duisburg-Essen.
Table 1 Characteristics of sarcoidosis patients in relation to disease stage and activity, and of healthy subjects.
Sarcoidosis Healthy
subjectsStage I
inactive
Stage I
active
Stage II
inactive
Stage II
active
Stage III
inactive
Stage III
active
n 21 9 14 13 5 5 18
Age [years] 52  15 41  14 48  11 51  16 49  15 60  14 48  15
Serum ACE (U/l) 49  13* 61  14* 41  8 81  13#* 25  4 66  23#* 28  9
Total protein concentration
in BAL supernatant
[mg/ml]
0.2  0.2* 0.2  0.12* 0.3  0.1* 0.2  0.1* 0.09  0.02 0.2  0.2#* 0.06  0.02
Albumin concentration in
BAL supernatant
[mg/ml]
0.06  0.07* 0.08  0.05* 0.04  0.04* 0.1  0.05#* 0.02  0.01 0.1  0.04#* 0.02  0.01
LDH in BAL supernatant
[U/l]
36.5  13 35  6 31  9 35  10 42  8* 40  10 31  9
BAL cell differentials
Macrophages [%] 75  21 49  20* 65  21* 62  17* 78  12 56  21 92  5
Neutrophil granulocytes [%] 0.7  3 2  3# 1  3 2  6 3  3 3  6 2  2
Lymphocytes [%] 24  20* 47  20* 34  21* 37  19* 17  11 42  15* 6  5
Cell viability [%] 91  7 90  5 87  5 91  6#* 86  8 88  7 90  13
CD4/CD8 ratio 5  3.5 8.85  5.88 3.2  2.11 5.4  3.51 0.7  3.43 6.5  3.7 Not measured
Suc-LLVY-AMC (pkat/mg) 3.5  5 2.6  2.5 3  1.8 2.9  3.3 3.9  2.3 3.1  3.5 3.1  3.4
BZ-VGR-AMC (pkat/mg) 3.4  3.3 2.3  1.7 3.8  2.5 4.3  5.1 7.9  6.1 3.7  4 2.7  1.7
Suc-LLE-AMC (pkat/mg) 1.9  2.1 2.3  2.4 1.4  1.4 1.1  0.9 2.5  1.8 2.2  2.6 1.4  1.1
Proteasome concentration
(ng/ml)
38  31 23  24 40  32 101  79#* 38  51 119  66#* 35  34
*p < 0.05 vs. healthy controls, #p < 0.05 vs. inactive sarcoidosis, same stage.
Means  SD from 67 patients with sarcoidosis and 18 healthy subjects.
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BAL was performed during local anesthesia using fiberoptic
bronchoscopy according to established guidelines [21]. The
CD4/CD8 ratio was measured by immunohistochemistry
[22]. The BAL cell differentials are shown in Tables 1 and 2.Table 2 Characteristics of sarcoidosis patients that
received immunohistochemistry.
Sarcoidosis Healthy
controlsActive Inactive
n 7 4 7
Age [years] 40  12 40  15 49  14
Smoking habits
No smokers or
former smokers
3 7 4
Active smokers 1 0 3
BAL cell differentials
Macrophages [%] 45  22* 53  27* 90  5
Neutrophil
granulocytes [%]
2.5  1.8 2.7  2.9 1.2  0.8
Lymphocytes [%] 50  22* 43  27* 8  5
CD4/CD8 ratio 4.3  2.5* 4.3  3.4* 1.8  1
Means  SD from 11 patients with sarcoidosis and 7 controls.
*p < 0.05 vs. healthy controls, #p < 0.05 vs. inactive sarcoid-
osis, same stage.Measurements in BAL supernatants
Determination of total 20S proteasome concentration
Total proteasome concentration was measured in BAL su-
pernatant in all sarcoidosis patients and in all healthy
subjects (Table 1) as described by Sixt et al. [18,23].
Proteasomal hydrolytic activity
The proteasomal activity (Table 1) was measured fluoro-
metrically in BAL supernatant in all patients and healthy
subjects using specific fluorogenic substrates and tech-
niques previously described [18]. Assays were performed in
duplicate and were averaged for each subject.
Total protein concentrations
Total protein concentration was determined after tri-
chloracetic acid (TCA) precipitation (5%), washing, and
resolubilization according to Lowry [25].
Lactate dehydrogenase (LDH) activity
Total (LDH1-LDH5) lactate dehydrogenase (LDH) activity was
measured by a kinetic UV-test (Diaglobal GmbH, Berlin)
using an optimized standard method (IFCC).
Immunocytochemistry of alveolar macrophages
Immunocytochemistry was used to investigate the expres-
sion of the 20S proteasome and of immunoproteasome
subunits in alveolar macrophages (AMs) obtained by BAL
from 11 patients (Table 2) with sarcoidosis (7 with active
disease; 8 females; age:40  12) and 7 controls (3 females;
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The method was applied as previously described [24].
All analyses (Table 3), including immunocytochemical
grading, were performed by two investigators blind to other
data and the patients’ disease classification. The interob-
server correlation was good and Spearman’s R-value was
0.89 (p Z 0.01).
Lung immunohistochemistry
Paraffin-embedded specimens of lung tissue from 11
different patients (5 with active sarcoidosis stage III and 6
with active sarcoidosis stage II; 7 female; age: 43  9.3
years) with clinically and histomorphologically confirmed
sarcoidosis who underwent open lung biopsy were randomly
retrieved from the archives of the Institute of Pathology of
the University Hospital Essen to assess the immunoex-
pression of the proteasome and immunoproteasome.
Normal lung parenchyma remote from a malignant tumor
served as controls and was obtained from patients under-
going lobectomy for lung cancer (n Z 3). Four mm thick
sections of formalin-fixed, paraffin-embedded tissues were
dewaxed and rehydrated according to standard procedures.
All antibodies (LMP2; LMP7 dilution 1:1000) were purchased
from Biotrend Chemikalien GmbH, Cologne.
Statistical analysis
Analyses were performed with SPSS version 13, (SPSS, Inc.,
Chicago, USA). Data are presented as means (SD) or as
medians (range), as appropriate. Comparisons of variables
between groups were performed by the ManneWhitney U-
test. Two groupswere comparedusing the unpaired t-test for
parametric data. The correlations of different parameters
were analyzed by Spearman rank. Wilcoxon’s Rank Test was
used to assess effects of potential inhibition of cleavage of
fluorogenic substrates by epoxomicin. An a-error (p) of less
than 0.05 was considered statistically significant.
Results
Presence of immunoproteasome proteins in lung
tissue and alveolar macrophages
Immunohistochemistry of lung tissue of patients with
sarcoidosis showed abundant reactivity for antibodiesTable 3 Expression of immunoproteasome subunits in
alveolar macrophages obtained from BAL.
Sarcoidosis Healthy
controls
p-Value
AM LMP2 positive (%) 60  33 69  31 0.58
AM score 85  59 86  52 0.96
AM LMP7 positive (%) 27  36 29  26 0.9
AM score 34  51 29  26 0.84
AM 20S proteasome
positive (%)
87  16 96  8 0.16
AM score 133  56 150  46 0.52
Means  SD from 11 patients with sarcoidosis and 7 healthy
subjects.
AM Z alveolar macrophage.directed against immunoproteasome proteins. Reactivity
was observed in type II pneumocytes of the alveolar
epithelium, in endothelial cells of intrapulmonary blood
vessels, and in interstitial inflammatory cells (Fig. 1).
Moreover, the epithelioid cells and the multinucleated
giant cells of the granulomas showed strong expression of
immunoproteasome. In normal lung parenchyma, some
immunoproteasome staining was observed occasionally in
the same cell types, but to a considerably lesser extent.
The percentage of BAL macrophages positive for LMP2,
LMP7, and 20S proteasome did not differ significantly be-
tween sarcoidosis and controls. Furthermore, the semi-
quantitative score for LMP2, LMP7, and 20S proteasome did
not differ significantly between sarcoidosis patients and
controls (Table 3).
Proteasome concentration and activity in the
alveolar space
Proteasomal concentrations in BAL supernatant from all
patients and healthy controls are presented in Table 1.
Overall, patients with active sarcoidosis (n Z 27) of all
stages (IeIII) had significantly greater proteasome concen-
trations than both patients (n Z 40) with inactive
sarcoidosis (78 ng/ml  73 vs. 39 ng/ml  33; p Z 0.013)
and healthy controls (35 ng/ml  34, p Z 0.002) (Fig. 2A).
Furthermore, alveolar proteasome concentration of
sarcoidosis patients with active disease stage II (101 ng/
ml  79; p Z 0.009) and stage III (119 ng/ml  66;
pZ 0.012) was significantly greater when compared to the
respective inactive stages (stage II: 40 ng/ml  32;
p Z 0.012; stage III: 38 ng/ml  51; p Z 0.047) (Fig. 2B).
There was no correlation between proteasome concen-
tration in BAL supernatant of sarcoidosis patients and their
CD4/CD8 ratio or differential cell counts in the BAL cell
pellet.
All specific fluorogenic peptides were hydrolyzed in BAL
supernatant of healthy subjects (Fig. 2C) and of patients
with sarcoidosis (Fig. 2D), and all hydrolyzing activities
were markedly inhibited (p < 0.001) by the highly specific,
proteasome inhibitor epoxomicin. No significant correlation
(pZ 0.37) was observed between proteasomal activity and
LDH activity in BAL supernatant. In contrast to the pro-
teasomal concentration in BAL supernatant, no significant
differences in the three specific (protein related) protea-
somal activities were observed between active and inactive
stages or when compared to healthy controls.
In BAL supernatant of sarcoidosis patients both total
protein (pZ 0.01) and albumin concentrations (pZ 0.001)
were significantly increased compared to healthy subjects
(Table 1).
Discussion
While the etiology of sarcoidosis is still unknown, it is
generally agreed upon that an immune reaction to a hith-
erto unknown agent is causative of the granulomatous
inflammation observed in organs involved by sarcoidosis
[20]. The immunoproteasome is a special form of the pro-
teasome complex that is involved in antigen presentation to
cells of the immune system and, therefore, might play an
Figure 1 Immunohistochemistry of lung tissue for 20S Proteasome, LMP2, and LMP7 obtained from a representative patient with
sarcoidosis (A, C, E) and a control subject (B, D, F). Note the strong immunoreactivity with antibodies directed against 20S Pro-
teasome, LMP2, and LMP7 in patients with sarcoidosis, in particular in epithelioid cells (asterisks) and multinucleated giant cells
(arrows) forming the typical epithelioid cell granuloma (A, C, E). In contrast, only weak positivity for these proteins was observed in
pneumocytes type II, respiratory epithelium lining bronchi and bronchioles and vascular endothelial cells in normal lung paren-
chyma of controls (B, D, F).
1538 S.U. Sixt et al.important role in the pathogenesis and/or course of
sarcoidosis. It has also been shown that during inflamma-
tion immunoproteasomes eliminate defective proteins and
protect cells against oxidative damage [26]. Against this
background, we investigated whether immunoproteasome
is present or not in tissues of patients with sarcoidosis and
in healthy controls, assessed its potential cellular source,
and quantified total alveolar proteasome concentration and
its biological activity.
Our data demonstrate that proteasomes are biologically
active in the alveolar space of patients with sarcoidosis, as
shown by hydrolysis of specific proteasomal fluorogenic
substrates, and its inhibition by epoxomicin. Furthermore,
in line with the quantitative investigations in BAL super-
natant, immunohistochemistry for immunoproteasome
detection performed on lung tissues of sarcoidosis patients
showed widespread reactivity with antibodies directed
against immunoproteasome proteins in a variety of celltypes. This included type II pneumocytes and respiratory
epithelial cells as well as the epithelioid cells and multi-
nucleated giant cells of sarcoidosis granulomas. In contrast,
the percentage of alveolar macrophages positive for LMP2,
LMP7, and 20S proteasome subunits did not differ signifi-
cantly between sarcoidosis patients and healthy controls.
Furthermore, while normal lung parenchyma occasionally
showed immunoreactivity for immunoproteasome in the
same cell types this was substantially and consistently
weaker compared to sarcoidosis patients. Moreover, the
granulomas with epithelioid cells and multinucleated giant
cells appeared to be a major source of immunoproteasome.
Together with our previous work [18], these findings
collectively indicate that the 20S proteasome is present in
lung alveoli under physiological conditions, whereas
immunoproteasome is present markedly increased in lung
tissues in sarcoidosis. Of note, sarcoidosis patients with
active stages II and III showed significantly increased total
Figure 2 A: Proteasome concentration in BAL supernatant of patients with active (nZ 27) and inactive sarcoidosis (nZ 40), and
in control subjects (n Z 18). Proteasome concentration was markedly and significantly greater in patients with active sarcoidosis
when compared to patients with inactive sarcoidosis and to healthy subjects. Box and whisker plots. B: Total proteasome con-
centration in BAL supernatant from 67 patients with sarcoidosis stages IeIII active and inactive (hatched columns) and from
controls (open column), respectively. Box and whisker plots. Extracellular alveolar proteasome concentration in BAL supernatant of
patients with active sarcoidosis (stages II and III) was significantly greater than those in healthy subjects or in patients with inactive
sarcoidosis. C: Hydrolysis of proteasome-specific fluorogenic substrates in BAL supernatant from 18 healthy subjects without (open
columns) and with 10 mM epoxomicin (hatched columns). Box and whisker plots. Hydrolyzing activity was present for all substrates
in BAL supernatant and each was significantly inhibited by epoxomicin. D: Hydrolysis of the proteasome specific fluorogenic sub-
strate Suc-LLVY-AMC in BAL supernatant from 67 patients with sarcoidosis. Box and whisker plots. Hydrolyzing activity was present
for all three fluorogenic substrates (data for BZ-VGR-AMC and Suc-LLE-AMC not shown) in BAL supernatants and each was also
significantly inhibited by epoxomicin (data not shown).
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healthy controls but also when compared to the respective
inactive stages of sarcoidosis. However, a potential limi-
tation of this study can be seen in the fact that we did not
perform PET or further biomarker investigation, like soluble
IL-2 receptor and neopterin, to exclude residual activity of
sarcoidosis in patients having inactive disease on the basis
of clinical-radiological- functional findings.
To our knowledge, this study is the first to address the
presence of immunoproteasome in lung tissue and the
activity of extracellular alveolar proteasome in sarcoid-
osis. Fluorogenic substrates, used in combination with
epoxomicin, the most potent, selective, and irreversible
proteasome inhibitor currently available, and an ELISA,
are accepted methods for analyzing proteasomal exis-
tence and activity [23,27,28]. In this study, we used an
ELISA technique for the measurement of proteasomal
concentration in the BAL supernatant. This techniquedoes not allow distinguishing quantitatively between the
20S proteasome and the immunoproteasome. However,
immunohistochemistry revealed that epithelioid cells and
multinucleated giant cells that make up the granulomas
are a major source of immunoproteasome in lungs
affected by sarcoidosis. Importantly, our data appear to
rule out alveolar cell lysis as a major source of the alve-
olar proteasome since no significant correlation was
observed between proteasomal activity and concentra-
tion in BAL of lactate dehydrogenase (LDH), a marker of
cell lysis, or the BAL cell count. Furthermore, alveolar
macrophages in sarcoidosis patients did not show
enhanced expression of immunoproteasome proteins.
However, lung tissue of patients with sarcoidosis showed
widespread reactivity with antibodies directed against
immunoproteasome in a variety of cell types including
type II pneumocytes. Accordingly, these cells could be
responsible for the presence of extracellular alveolar
1540 S.U. Sixt et al.proteasome in sarcoidosis. Further investigations have to
address the potential mechanisms for proteasome trans-
port into the alveolar lumen.
The presence of immunoproteasome proteins (LMP2 and
LMP7) in the noncaseating granulomas allows the formula-
tion of two hypotheses with regard to sarcoidosis: 1) The
immunoproteasome is a physiological inflammatory
response to a yet unidentified infectious agent or antigen,
and 2) it is possibly involved in the intracellular processing
of the antigen to evoke a specific immune response.
Conclusions
In summary, immunoproteasome is markedly expressed in
tissues affected by sarcoidosis. Thus, the immunoprotea-
some likely plays an important role in initiating and/or
sustaining the inflammatory response characteristic of
sarcoidosis. These findings are in line with the data of Baker
and coworkers [29] who demonstrated increased 20S/26S
proteasome expression in interstitial fibrotic lung disease
including sarcoidosis. Nevertheless, the exact role of the
proteasome/immunoproteasomes in sarcoidosis is hitherto
unknown. Due to the many catalytic properties and multi-
ple target proteins of the proteasome, the pathogenetic
mechanisms driven by proteasome may be numerous. The
proteasome expression in BAL fluid from sarcoidosis pa-
tients seems to be stage dependent. This finding might
prompt further studies to investigate the proteasome as a
routine serum biomarker to monitor disease activity or
drive therapeutical decisions. If the current results will be
confirmed, proteasome inhibitors such as bortezomib might
be considered as potential therapeutic agents for sarcoid-
osis in the future.
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